Page last updated: 2024-09-04

n-acetylglucopyranosylamine and valine

n-acetylglucopyranosylamine has been researched along with valine in 1 studies

Compound Research Comparison

Studies
(n-acetylglucopyranosylamine)
Trials
(n-acetylglucopyranosylamine)
Recent Studies (post-2010)
(n-acetylglucopyranosylamine)
Studies
(valine)
Trials
(valine)
Recent Studies (post-2010) (valine)
170315,4651,1763,932

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hashimoto, K; Horino, T; Inoue, K; Kagawa, T; Matsumoto, R; Morita, T; Takao, T1

Other Studies

1 other study(ies) available for n-acetylglucopyranosylamine and valine

ArticleYear
Angiotensin II receptor blocker inhibits tumour necrosis factor-alpha-induced cell damage in human renal proximal tubular epithelial cells.
    Nephrology (Carlton, Vic.), 2008, Volume: 13, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Apoptosis; Caspase 3; Caspase 7; Cell Survival; Cells, Cultured; Cytoprotection; Dose-Response Relationship, Drug; Enzyme Activation; Epithelial Cells; Glucosamine; Humans; Imidazoles; Kidney Tubules, Proximal; L-Lactate Dehydrogenase; NADPH Oxidases; Pyridines; Receptor, Angiotensin, Type 2; Receptors, Tumor Necrosis Factor, Type I; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan

2008